Marché de l’IA en bioinformatique au Moyen-Orient et en Afrique – Tendances et prévisions du secteur jusqu’en 2029

Analyse et taille du marché de l'IA en bioinformatique au Moyen-Orient et en Afrique

La baisse du coût du séquençage génétique a renforcé la demande du marché. L'augmentation des dépenses de santé pour de meilleurs services de santé est également attribuée à la croissance du marché. Les principaux acteurs du marché se concentrent fortement sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, la demande croissante en bioinformatique et l'augmentation du financement public-privé pour la bioinformatique contribuent également à la demande croissante du marché.

Le marché de l'IA en bioinformatique au Moyen-Orient et en Afrique connaît une croissance au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs du marché et de la disponibilité de services avancés. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D pour lancer de nouveaux services sur le marché. Les progrès croissants de la technologie bioinformatique stimulent encore la croissance du marché. Cependant, le coût élevé des instruments et les problèmes de cybersécurité en bioinformatique pourraient entraver la croissance du marché de l'IA en bioinformatique au Moyen-Orient et en Afrique au cours de la période de prévision.

Data Bridge Market Research analyse que le marché de l'IA en bioinformatique devrait atteindre la valeur de 588,86 millions USD d'ici 2029, à un TCAC de 31,3 % au cours de la période de prévision. Les « services » représentent le segment technologique le plus important du marché de l'IA en bioinformatique en raison des développements rapides des voies technologiques pour commercialiser l'utilisation de l'IA portable en bioinformatique. Le rapport sur le marché de l'IA en bioinformatique couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.         

Market Definition

Bioinformatics is a sub-discipline that has to do with the analysis of sequences of biological molecules. It usually refers to genes, DNA, RNA, or protein and is particularly useful in comparing genes and other sequences in proteins and different sequences within an organism or between organisms, looking at the evolutionary relationships between organisms, and using the patterns that exist across DNA and protein sequences to figure out what their function is.

Bioinformatics combines computer programming, big data, and molecular biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.

From genetics to toxicology to mycology and radiobiology, there are scores of branches of Biology to specialize in. And out of the many, bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store, and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of computer science, statistics, and biology to develop software applications for understanding the biological data like DNA sequencing, protein analysis, evolutionary genetics, and others.

• In the coming future, important decisions related to bioinformatics, on drug discovery will be made by individuals who not only understand the biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.

AI in Bioinformatics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

• Growing demand for bioinformatics

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into the molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, computer programmers, mathematicians, or database managers to learn the foundations of biology.

• Reduction in the genetic sequencing cost

The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.

• Increasing public-private sector funding for bioinformatics

In order to improve the workflow for bioinformatics, the federal agencies, the public, and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which, in turn, have improved the quality of these services.

• High cost of instrumentation

The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated and needs high validation and other specification, which increase. Genomics instruments are also equipped with advanced features and functionalities and are thus priced at a premium, ranging between ~USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.

• Strategic initiatives of key players

The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market.

By successfully working with new technology firms to ensure continued growth, creativity, and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes and engage patients more.

Companies discover and develop advanced bioinformatics products, and these companies are launching new initiatives and collaborating with other key players to deliver more reliable results and services.

• Advancement in bioinformatics technology

The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology up-gradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications, and there are high chances in the advancement of bioinformatics techniques in the forecasted period.

• Lack of skilled professionals to perform AI based bioinformatics technology

One of biology's most rapidly developing fields of study is bioinformatics, which involves the development and use of computational tools for the collection, archiving, organisation, analysis, and visualisation of biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualisation of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.

Post COVID-19 Impact on AI in Bioinformatics Market

During the pandemic, the North bioinformatics sector is one that focuses on using a combination of biology and information technology. At the heart of the industry is biological data, which is analyzed and transformed using IT techniques. Bioinformatics has always had huge potential when it comes to providing essential support to many areas of scientific research. The tools that bioinformatics can provide allow scientists to get to grips with larger data sets to mine and analyses them to discover crucial information that could lead to key discoveries. Genetics and genomes have been the primary focus of bioinformatics in recent years, including comparative genomics, DNA microarrays, and functional genomics.

The growth of the AI in bioinformatics market is increasing with the growing demand for analysis tools in drug discovery and development and the integration of AI in various fields to interpret the data more conveniently. Hence, the market is expected to grow significantly in the forecast period, whereas the cost and the complexity of AI integration may hamper the market growth. The intervention of COVID-19 has increased the R&D activities, which in turn positively add to the market growth.

Recent Developments

• In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped the company to increase its Middle East and Africa presence in the market.
• In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company Middle East and Africa, servicing clients in the life sciences, biotechnology, and pharmaceutical industries. JADBio is a robust Automated Machine Learning platform that allows intuitive, timely, and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.

Middle East and Africa AI in Bioinformatics Market Scope

Middle East and Africa AI in bioinformatics market are segmented on the basis of offering, type, products and services, application, and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Services
•  Software
•  Others

Sur la base de l’offre, le marché de l’IA en bioinformatique au Moyen-Orient et en Afrique est segmenté en services, logiciels et autres.

Taper

• Apprentissage automatique
• Apprentissage profond
• Autres

Sur la base du type, le marché de l’IA en bioinformatique au Moyen-Orient et en Afrique a été segmenté en apprentissage automatique, apprentissage en profondeur et autres.

Produits et services

• Services de bioinformatique
• Plateformes bioinformatiques
• Outils de gestion des connaissances

Sur la base des produits et services, le marché de l’IA en bioinformatique au Moyen-Orient et en Afrique a été segmenté en services bioinformatiques, plateformes bioinformatiques et outils de gestion des connaissances.

Application

• Génomique
• Chimioinformatique et conception de médicaments
• Protéomique
• Séquençage de l'ADN
• Biologie des systèmes
• Transcriptomique
• Exploration de texte
• Microarrays
• Métabolomique
• Autres

Sur la base des applications, le marché de l'IA en bioinformatique au Moyen-Orient et en Afrique a été segmenté en génomique, chimio-informatique et conception de médicaments, protéomique, séquençage d'ADN, biologie des systèmes, transcriptomique, exploration de texte, microarrays, métabolomique et autres.

Secteur

• Biotechnologie médicale
• Biotechnologie animale
• Biotechnologie végétale
• Biotechnologie environnementale
• Biotechnologie médico-légale
• Autres

Sur la base du secteur, le marché de l’IA en bioinformatique au Moyen-Orient et en Afrique a été segmenté en biotechnologie médicale, biotechnologie animale, biotechnologie végétale, biotechnologie environnementale, biotechnologie médico-légale et autres.

Analyse/perspectives régionales du marché de l'IA en bioinformatique

Le marché de l’IA en bioinformatique est analysé et des informations sur la taille et les tendances du marché sont fournies par pays, offre, type, produits et services, application et secteur référencés en Afrique du Sud, en Arabie saoudite, aux Émirats arabes unis, en Israël, en Égypte et dans le reste du Moyen-Orient (MEA) dans le cadre du Moyen-Orient et de l’Afrique (MEA). L’Afrique du Sud devrait dominer le marché de l’IA en bioinformatique au Moyen-Orient et en Afrique en raison de l’augmentation des dépenses de recherche et développement et de la demande d’outils d’analyse informatique avancés pour analyser les études.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, l'analyse des tendances techniques des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché de l'IA en bioinformatique

Le paysage concurrentiel du marché de l'IA en bioinformatique fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que les entreprises qui se concentrent sur le marché de l'IA en bioinformatique.

Certains des principaux acteurs opérant sur le marché de l'IA en bioinformatique sont SOPHiA GENETICS, Biomax Informatics Inc., QIAGEN, NeoGenomics Laboratories, Eurofins Scientific, Illumina, Inc., Thermofisher Scientific, Inc., Dassault Systèmes, SomaLogic Operating Co., Inc. entre autres.

SKU-69031